Inozyme Pharma (INZY)

Inozyme Pharma Stock Analysis & Ratings

INZY Stock Chart & Stats

Day’s Range$3.99 - $4.295
52-Week Range$3.54 - $19.58
Previous Close$4
Average Volume (3M)174.62K
Market Cap$169.61M
P/E Ratio-1.6
Next EarningsSep 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10
EPS (TTM)-2.64



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $3.54 and its highest was $19.58 in the past 12 months.
    What is Inozyme Pharma’s market cap?
    Inozyme Pharma’s market cap is $169.61M.
      What is Inozyme Pharma’s price target?
      The average price target for Inozyme Pharma is $27.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $40.00 ,the lowest forecast is $20.00. The average price target represents 547.75% Increase from the current price of $4.23.
        What do analysts say about Inozyme Pharma?
        Inozyme Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Inozyme Pharma’s upcoming earnings report date?
          Inozyme Pharma’s upcoming earnings report date is Sep 08, 2022 which is in 115 days.
            How were Inozyme Pharma’s earnings last quarter?
            Inozyme Pharma released its earnings results on May 10, 2022. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.792 by $0.082.
              Is Inozyme Pharma overvalued?
              According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
                Does Inozyme Pharma pay dividends?
                Inozyme Pharma does not currently pay dividends.
                What is Inozyme Pharma’s EPS estimate?
                Inozyme Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Inozyme Pharma have?
                Inozyme Pharma has 40,100,000 shares outstanding.
                  What happened to Inozyme Pharma’s price movement after its last earnings report?
                  Inozyme Pharma reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.792. Following the earnings report the stock price went up 10.298%.
                    Which hedge fund is a major shareholder of Inozyme Pharma?
                    Among the largest hedge funds holding Inozyme Pharma’s share is Deerfield Management Company, LP. It holds Inozyme Pharma’s shares valued at 16M.


                      Inozyme Pharma Stock Analysis

                      Smart Score
                      Price Target
                      ▲(547.75% Upside)
                      Strong Buy
                      The Inozyme Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Inozyme Pharma

                      Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis